Severe Acute Respiratory Syndrome
Conditions
Interventions
Through telephone contact, an interview will be conducted to collect data related to sociodemographic characteristics, details of the use of antimalarials and immune-mediated rheumatic diseases (indic
Other
Sponsors
Socidade Brasileira de Reumatologia
Departamento de Ciência e Tecnologia - Decit
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age greater than or equal to 18 years; use of antimalarial drugs for at least 30 days before inclusion; diagnosis of immune mediated rheumatic disease defined according to American College of Rheumatology (ACR) or European League against Rheumatism (EULAR) criteria: rheumatoid arthritis (RA), systemic lupus erythematosus (SLE, Sjogren's syndrome (SS), systemic sclerosis, myopathies inflammatory diseases, mixed connective tissue disease (DMTC), systemic sclerosis (ES); diagnosis of osteoarthritis (OA) of hands (subgroup).
Exclusion criteria
Exclusion criteria: Previous use of antimalarial, but not current in the last 6 months; history of solid organ or bone marrow transplantation; neoplasm of solid organs or lymphatic or myeloproliferative lineage in the last 12 months with or without adjuvant chemotherapy; use of intravenous human immunoglobulin in the last 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the incidence of SARS-CoV-2 infection, suspected or confirmed, during the follow-up period, comparing the frequency between the patient and his home contacts included in the study, according to the definitions of the Ministry of Health of Brazil.;Determine the frequency of deaths in suspected or confirmed cases of SAR-Cov-2 infection in patients with rheumatic diseases by comparing with their home contacts included in the study;Evaluate the need for hospitalization due to SARS-CoV-2 infection in patients with rheumatic diseases compared to their home contacts included in the study, including the following parameters: total hospitalization time, need for admission to the intensive care unit, need for mechanical ventilation during hospitalization | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the general clinical differences of COVID-19 in the comparison between rheumatic patients and non-rheumatic controls. The data on the incidence of symptoms related to COVID-19 in patients with rheumatic diseases and their controls will be compared, both in cases considered mild (flu-like symptoms) and among severe cases (respiratory diseases, neurological diseases, gastrointestinal diseases). | — |
Countries
Brazil
Contacts
Public Contactcláudia marques
Universidade Federal de Pernambuco
Outcome results
None listed